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Abstract
Ten new 3,4-seco betulinic acid (BA) derivatives were designed and synthesized. Among them,
compounds 7–15 exhibited enhanced chemopreventive ability in an in vitro short-term 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced Epstein-Barr virus early antigen (EBV-EA)
activation assay in Raji cells. Specifically, analogs with a free C-28 carboxylic acid, including 7,
8, 11, and 13, inhibited EBV-EA activation significantly. The most potent compound 8 displayed
100% inhibition at 1 × 103 mol ratio/TPA and 73. 4%, 35. 9%, and 8. 4% inhibition at 5 × 102, 1 ×
102, and 1 × 10 mol ratio/TPA, respectively, comparable with curcumin at high concentration and
better than curcumin at low concentration. The potent chemopreventive activity of novel seco A-
ring BAs (8 and 11) was further confirmed in an in vivo mouse skin carcinogenesis assay.
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The concept of chemoprevention has grown over the past few decades. Cancer is a
multistage process, and the question of how to stop the progression stage of its development
has gradually drawn increasing attention. 7 The Epstein-Barr virus early antigen (EBV-EA)
activation assay was been established to quickly evaluate chemopreventive activity in vitro,8
while a two-stage mouse skin carcinogenesis assay can further assess in vivo activity. 9, 10
Development of these biological assays has greatly facilitated research on chemopreventive
agents.
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Betulinic acid (BA, Figure 1) and its derivatives reportedly possess various pharmacological
functions, such as anti-cancer, anti-HIV, anti-inflammatory, anti-malarial, and anti-bacterial
effects. Prior modifications of BA have focused mainly on the C-3 hydroxyl, C-28
carboxylic acid, and C-30 allylic positions. 1,2 Recently, we introduced short fatty acids at
the C-3 position of BA and the resulting BA analogs demonstrated excellent cancer
chemopreventive activity in both EBV-EA activation and two-stage mouse skin
carcinogenesis assays. 3 Akihisha et al. also reported that compound 1 with a 3,4-seco
lanostane structure exhibited inhibitory effects against EBV-EA activation in Raji cells. 4 In
addition, some limonoids [e. g. nomilin (2)] with an A-ring lactone showed anti-proliferative
effects on neuroblastoma cancer cells (SH-SY5Y). 5 The mechanism of action involved
apoptosis induction, cancer cell cycle arrest and aneuploidic effects. 5 Furthermore, other
studies reported that 3,4-seco ursolic acid derivatives induced cell cycle arrest and apoptosis
in a human bladder cancer cell line (NTUB1). 6 Based on these discoveries, a group of novel
3,4-seco BA analogs 7–16 were designed to enhance the chemopreventive activity. Herein,
this paper reports the design, synthesis and biological evaluation of these novel compounds.
3,4-Seco BA analogs 7–16 were designed and synthesized through oxepanone A-ring
intermediates 5 and 6. A N-heptane acetamide side chain was included in our analog design
(9, 10 and 14–16), because this group enhanced the biological activity of BA in our prior
studies. 11 Initially, betulin, a commercially available pentacyclic triterpene, was oxidized
with Jones reagent to provide compound 3 with a ketone at C-3 and carboxylic acid at C-28.
Baeyer-Villiger reaction of 3 using 3-chloroperbenzoic acid (mCPBA) produced 5 with an
oxepanone A-ring. Because prenyl-like groups have played an important role in cancer
preventive effects in our prior studies,3 acid-catalytic lactone ring opening in MeOH was
employed to produce the 4-methylene-3-methyl ester 7. Hydrolysis of 7 gave the
corresponding dicarboxylic acid 8. Hydroboration-oxidation of 7 produced the alcohol 11,
which was esterified using various acid anhydrides, such as 2,2-dimethylsuccinic and acetic
anhydrides, to provide 12 and acetate 13, respectively. For the preparation of N-heptane
acetamide analogs, the related carboxylic acids 3 and 13 were treated with oxalyl chloride
and heptane-1,7-diamine followed by acetic anhydride to obtain 4 and 14, respectively.
Analogs 6, 9 and 10 were prepared from 4 through the same procedure as for the preparation
of 5, 7 and 8. The methyl ester and acetate on 14 were hydrolyzed to produce 15, which was
treated with dimethylsuccinic anhydride to provide 16.
Compounds 6–16 were evaluated in an in vitro EBV-EA inhibition assay and the results are
shown in Table 1. Bevirimat and BA were also evaluated and curcumin was used as a
positive control. As seen in the results, 3,4-seco BA analogs showed substantial
chemopreventive activity. Four compounds 7, 8, 11, and 13 significantly inhibited EBV-EA
activation, showing 100% inhibition at the highest tested concentration. All four compounds
contained a C-28 carboxylic acid and showed better activity than corresponding compounds
with a C-28-N-heptane acetamide (compare 7/9, 8/10, 13/14). Three additional compounds
with a C-28-N-heptane acetamide (compare 6, 15, 16) were also less active. The most active
compound 8 also contained a C-3 carboxylic acid and C-4 methylene in addition to the C-28
carboxylic group. It displayed 100% inhibition at 1 × 103 mol ratio/TPA, and 73. 4%, 35.
9% and 8. 4% inhibition at 5 × 102, 1 × 102, and 1 × 10 mol ratio/TPA, respectively, with an
IC50 value of 295 mol ratio/TPA. Even at the lowest concentration (1 × 10 mol ratio/TPA), 8
exhibited greater inhibitory activity than curcumin, a known cancer chemopreventive agent.
This result may be because the C-5 isopropenyl group is similar to a prenyl group, which has
been an effective modification in cancer prevention research. 3 Considering the C-3
substituent, compound 8 with a C-3 carboxylic acid was slightly more active than 7 with a
C-3 methyl ester. Finally, regarding C-4 substituents, analog 7 with a C-4 methylene was
slightly more potent than 11 and 13 with hydroxymethyl and acetoxymethyl, respectively.
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Two of the most active compounds, 8 and 11, were further evaluated in a mouse skin
carcinogenesis assay (Figure 1). Mouse skin papillomas were induced by DMBA and
promoted by TPA. Inhibitory effects of 8 and 11 were monitored and determined over 20
weeks by both the percentages of papilloma-bearing mice (Figure 2A) and the average
numbers of papillomas/mouse (Figure 2B). Although skin papillomas still appeared, their
occurrence was delayed for three weeks in both treated groups compared with the control
group. At weeks 8 and 11, 50 and 100% of mice in the positive control group bore
papillomas, while only 0–10% and 10–20% of mice in the 8- and 11-treated groups
displayed papillomas. The average numbers of papillomas/mouse at week 8 and 11 were 1. 2
and 2. 7 for the positive control group, but only 0 and 0. 4, respectively, for the 8-treated
group. The in vivo results are quite promising and consistent with the in vitro data.
The structure-activity relationship (SAR) trends are summarized as follows. The 3,4-seco
structural feature can significantly increase chemopreventive activity. A C-3 carboxylic acid
is better than a methyl ester. A C-4 methylene is better than hydroxymethyl or
acetoxymethyl groups. A C-28 carboxylic acid is considerably better than N-heptane
acetamide. Among all new compound, 7, 8, 11, and 13 significantly inhibited TPA induced
EBV-EA activation.
In this study, new BA derivatives were designed, synthesized and evaluated for cancer
chemopreventive activity. Most of the newly synthesized compounds showed significant
cancer prevention effects. In an in vitro EBA-EA assay, 8 was the most potent derivative
with comparable inhibitory ability to curcumin, a known chemopreventive agent, at high
concentration and better inhibitory ability at low concentration. Compounds 8 and 11
delayed occurrence of papillomas in an in vivo mouse skin carcinogenesis assay. These
results provided convincing evidence that 3,4-seco modification can greatly enhance the
chemopreventive activity of BA analogs.
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Figure 2. Inhibitory effects of compounds 8 and 11 on DMBA-TPA mouse skin carcinogenesis
Tumor formation in all mice was initiated with DMBA (390 nmol) and promoted with TPA
(1. 7 nmol) twice weekly beginning 1 week after initiation. (A) Papilloma percentage in
mice. (B) Average number of papillomas/mouse. (◆) Control TPA alone; (△) TPA +
compound 11 (85 nmol); (■) TPA + compound 8 (85 nmol). After 20 weeks of promotion, a
significant difference in the number of papillomas/mouse between the treated groups and the
control group was evident (p < 0. 05).
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Scheme 1. Synthesis of 3,4-seco Betulinic Acid Derivatives
Reagents and Conditions: (a) Jone’s oxidation, (b) Pd/C, HOAc, (c) 1) (CO)2Cl2,
NH2(CH2)7NH2, CH2Cl2, 2) Ac2O,
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